ArticleCancer immunology, immunotherapy : CII2025
Soluble PD-L1 (sPD-L1) as a biomarker of durable response and survival in patients with advanced non-small cell lung cancer (NSCLC) treated with first-line immune checkpoint inhibitors (ICIs).
Article in Cancer immunology, immunotherapy : CII, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Soluble Isoforms of PD-1 and PD-L1 in Non-Small Cell Lung Cancer: Correlation with Tumor Stage, Longitudinal Analysis and Prognostic Implications.Journal of personalized medicine · 2026Article
- Strategies to target PD-1/PD-L1 in the tumor microenvironment.Cellular oncology (Dordrecht, Netherlands) · 2026Review
- Progress in perioperative immunotherapy for lung cancer and analysis of therapy (Review).Oncology letters · 2026Review
- The evolving role of neoadjuvant immunotherapy in resectable non-small cell lung cancer: a narrative review.Journal of thoracic disease · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionThere is a need for biomarkers to predict response and survival to immune checkpoint inhibitors (ICIs) in patients with advanced non-small cell lung cancer (NSCLC). Soluble PD-L1 (sPD-L1) has shown biomarker potential. The objective of this study was to evaluate sPD-L1 in patients with advanced NSCLC treated with first-line ICIs.
methodsWe constructed three prospective cohorts of patients with advanced NSCLC treated with first-line chemotherapy (CT), (Cohort #1), ICIs, or CT-ICIs (Cohort #2 and #3). Plasma was collected at baseline and at first tumour evaluation. sPD-L1 levels were measured by ELISA and compared to response and survival metrics.
resultsPatients were mostly male smokers with adenocarcinomas. Baseline sPD-L1 was lower in responders versus (vs) non-responders in Cohort #2 (p = 0.0233). Patients with low baseline sPD-L1 had longer OS in Cohorts #2 and #3: median OS 18.0 months vs 4.0 months, (p = 0.0277) and not reached (NR) vs 13.0 months (p = 0.0360). First tumour evaluation sPD-L1 was lower in responders in Cohorts #1 (p = 0.0138) and #2 (p = 0.0009). Patients with low sPD-L1 at first tumour evaluation had longer OS in Cohort #2: 45.0 months vs 12.5 (p = 0.0041). Patients with stable/decreasing sPD-L1 had longer OS throughout the Cohorts: median OS of 15.5 vs 6.0 months, 45.0 vs 14.0 months and not reached (NR) vs 17.0 months in Cohorts #1, #2 and #3. In vitro studies confirmed that cancer and immune cells secreted sPD-L1 and that NSLC patient plasma has the capacity to inhibit lymphocyte proliferation.
conclusionsPD-L1 has prominent biomarker potential in advanced NSCLC treated with first-line ICIs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.